Ascentage Pharma Aktie - AAPG

Professionelle Tools für Privatanleger.

Premium

Current Price

18,70

Gebot

18,23

Fragen

19,23

Volumen

8.496

18,47 Tagesbereich 19,06

0,00 52-Wochen-Bereich 0,00

Handelsende

19,00

Handelsbeginn

18,83

Letzte Trade

100

18.55

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

US$ 159.450

VWAP

18,7676

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX:...

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the...

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

AAPG - Frequently Asked Questions (FAQ)

What is the current Ascentage Pharma share price?

The current share price of Ascentage Pharma is US$ 18,70

What is the 1 year trading range for Ascentage Pharma share price?

Ascentage Pharma has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
CRVOCervoMed Inc	US$ 6,15 (160,59%)	158,89M
ZENAZenaTech Inc	US$ 4,5505 (61,94%)	6,89M
OPRXOptimizeRx Corporation	US$ 6,265 (51,33%)	16,41M
SSPEW Scripps Company	US$ 2,05 (43,36%)	18,27M
GRPNGroupon Inc	US$ 13,9807 (43,10%)	11,17M
HITHealth In Tech Inc	US$ 1,32 (-82,31%)	16,73M
SPHLSpringview Holdings Ltd	US$ 1,24 (-79,33%)	10,7M
APDNApplied DNA Sciences Inc	US$ 0,0619 (-57,89%)	35,11M
ZYXIZynex Inc	US$ 3,39 (-51,57%)	3,82M
HEPAHepion Pharmaceuticals Inc	US$ 0,0488 (-41,90%)	79,16M
STISolidion Technology Inc	US$ 0,174899 (38,70%)	506,61M
NVDANVIDIA Corporation	US$ 115,74 (6,42%)	298,41M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,1432 (15,59%)	202,29M
VSTEVast Renewable Ltd	US$ 0,6182 (23,66%)	184,27M
CRVOCervoMed Inc	US$ 6,15 (160,59%)	154M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ascentage Pharma Group International (AAPG)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

AAPG Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

AAPG - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Ascentage Pharma Group International (AAPG) Börsenkurse

Ascentage Pharma Group International (AAPG)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

AAPG Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

AAPG - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR